CBS News finds doctors and nurses promoting unapproved retatrutide

A CBS News investigation reported on June 8, 2026, that some U.S. doctors and nurses are promoting and prescribing retatrutide, an experimental weight-loss drug that has not been approved by the Food and Drug Administration ^[1]. Retatrutide is not approved for any use in the United States ^[1][2].

The investigation identified more than 120 websites and more than 50 clinics across the country that were actively selling or promoting the unapproved medication ^[2]. Many of those operations are staffed by licensed physicians and nurse practitioners who say the clinical evidence is strong enough to justify bypassing the standard regulatory timeline ^[2]. One provider, Jack Mutnick of Renew Med Spa Plus, defended the decision by saying he is confident in Eli Lilly's clinical trial results and believes patients should not have to wait for the official government stamp, according to Drug Topics ^[2].

Retatrutide is a triple agonist that acts on the glucose-dependent insulinotropic polypeptide, GLP-1 and glucagon receptors. The design is intended to reduce appetite, increase energy expenditure and break down lipids ^[2]. In the phase 3 TRIUMPH-1 trial, the 12 mg dose produced an average weight loss of 28.3% over 80 weeks, and nearly half of participants lost 30% or more of their body weight ^[2].

Even so, the drug remains investigational. The FDA has said retatrutide cannot be used in compounding under federal law because it is not a component of any FDA-approved drug ^[2]. Some clinics source products labeled "research use only" or "not for human consumption" — labeling intended to shield sellers from liability — while distributing the product for human use with dosing instructions, according to Drug Topics ^[2].

Human exposures to retatrutide reported to U.S. poison centers rose 265% in the first four months of 2026 compared with the end of 2025 ^[2]. Unapproved or counterfeit products can contain unknown ingredients, contaminants or the wrong concentration of active drug ^[2]. Longer-term concerns cited in the Journal of the American College of Clinical Pharmacy include thyroid C-cell tumors, pancreatitis and psychiatric events such as depression and suicidal ideation, which require the monitoring that comes with an approved regulatory framework ^[2]. Poor refrigeration during shipping has also been flagged as a quality problem for compounded GLP-1 products ^[2].

"The excitement surrounding emerging obesity therapies is understandable, especially when early clinical trial results appear promising," said Jennifer Goldman, PharmD, a professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences. "However, until a medication completes the regulatory review process, important questions may remain regarding long-term safety, appropriate dosing, drug interactions, adverse effects, and patient selection" ^[2]. Goldman added, "Patients should never have to choose between access and safety" ^[2].

Why it matters for patients

Anyone who buys retatrutide today is getting a product that has not gone through FDA review for safety, effectiveness or purity, because no approved version exists ^[1][2]. The only legal pathway to the drug at this point is enrollment in a clinical trial, according to the review in Drug Topics ^[2].

That means there is no federal assurance about what is in a vial, whether the dose listed on a label is accurate, or how the product was stored ^[2]. Pharmacists quoted in the report say patients should be directed toward approved therapies or trial enrollment instead ^[2]. How many of the poison center exposures involved serious harm has not been reported ^[2].

What happens next

Official regulatory submission for retatrutide is not anticipated until late 2026, with a projected market launch unlikely before early 2028 ^[2]. Those dates are projections, not FDA commitments. It has not been reported whether federal or state regulators have taken action against the clinics and websites identified in the investigation ^[1][2].